Jacobs Solutions stock presents a valuation divide, with a Discounted Cash Flow analysis indicating the shares are about 38.6% undervalued relative to an estimated intrinsic value of $202.91 per share, while a price-to-earnings comparison shows the stock trading at a premium. The DCF model uses a latest twelve-month free cash flow of approximately $451.5 million and assumes growing cash flows, supported by recent contract wins including a $1.7 billion role on the Wadsworth Center public health laboratory and large transport infrastructure projects. In contrast, Jacobs Solutions trades at about 35.9 times earnings, above the peer average of 28.4 times and a tailored fair P/E of 28.9 times, suggesting investors are already paying a higher price for the earnings profile. The stock has returned 27.7% over the past three years but declined 4.6% in the last year, and broader value checks yield a mixed score of 3 out of 6, leaving the key question of whether execution on complex projects will realize the DCF-implied upside or if market multiples correctly price the risks.
Jacobs Solutions Inc.DCF analysis suggests 38.6% undervaluation relative to intrinsic value of $202.91 per share